Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Last trade$1.19
Day change-$0.07 (-5.56%)
Day range$1.10 – $1.32
Volume429,561
Market cap$28M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$27.58M
Price / earnings
—
Price / book
0.48×
Price / sales
—
EV / sales
—
EV / EBITDA
0.43×
Profitability
Earnings per share
-$3.32
Return on assets
-112.28%
Return on equity
-126.3%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.11×
Quick ratio
9.11×
Cash ratio
8.58×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$66.81M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AARD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.05M
$4.63M
$5.9M
$4.41M
$3.97M
$2.7M
$2.72M
Research and development
$15.67M
$10.46M
$16.57M
$14.3M
$13.74M
$13.15M
$7.76M
Total operating expenses
$19.72M
$15.08M
$22.46M
$18.7M
$17.7M
$15.85M
$10.47M
Operating income
-$19.72M
-$15.08M
-$22.46M
-$18.7M
-$17.7M
-$15.85M
-$10.47M
Interest expense
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$19.19M
-$14.39M
-$21.59M
-$17.6M
-$16.32M
-$14.37M
-$9.31M
Income taxes
$0
$0
$0
$0
$0
$0
$0
Net income
-$19.19M
-$14.39M
-$21.59M
-$17.6M
-$16.32M
-$14.37M
-$9.31M
Net income attributable to common shareholders
-$19.19M
-$14.39M
-$21.59M
-$17.6M
-$16.32M
-$14.37M
-$9.31M
EBITDA
-$19.71M
-$15.07M
-$22.45M
-$18.69M
-$17.69M
-$15.84M
-$10.47M
Basic earnings per share
-$0.88
-$0.66
-$0.99
-$0.80
-$0.75
-$0.66
-$0.71
Diluted earnings per share
-$0.88
-$0.66
-$0.99
-$0.80
-$0.75
-$0.66
-$0.71
Recent news
Company coverage with links to the original publishers.
Aardvark Therapeutics reported exploratory efficacy data from its early-terminated Phase 3 HERO trial for ARD-101, a hunger-suppressing therapy for Prader-Willi syndrome. The drug showed modest reductions in hyperphagia scores and was generally well-tolerated, though one cardiac serious adverse event occurred at the highest dose in combination with another drug. The FDA lifted the clinical hold, allowing the company to resume development at lower doses and plan a new Phase 3 trial.
Aardvark Therapeutics, Inc. (AARD) has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates over the past three months, with consensus estimates increasing 12.4%. The upgrade reflects improved business fundamentals and positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation.
Rosen Law Firm is notifying investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.
Rosen Law Firm reminds investors in Aardvark Therapeutics who purchased securities during the IPO on February 13, 2025 through May 14, 2026 of an October 13, 2026 deadline to nominate a lead plaintiff. The lawsuit alleges that defendants made material false and misleading statements regarding the safety and commercial prospects of ARD-101, causing investor losses when the truth was revealed.
A class action lawsuit has been filed against Aardvark Therapeutics in the U.S. District Court for the Southern District of California. The lawsuit alleges that defendants made materially false and misleading statements in the company's IPO registration statement and throughout the class period (February 13, 2025 to May 14, 2026), specifically regarding the safety and commercial prospects of their drug ARD-101. Investors who purchased shares during this period can apply to be lead plaintiff by October 13, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.